USA 04/26/2019 – Indica Labs and IONpath announced today that a co-marketing agreement has been established to jointly promote their respective technologies for tissue-based, multiplexed biomarker research.

IONpath’sTM MIBIscope platform uses secondary ion mass spectrometry (SIMS) to image antibodies tagged with monoisotopic metal reporters, permitting simultaneous visualization of 40+ markers in any tissue type, including FFPE, with unmatched resolution and sensitivity.

“With capacity to measure dozens of proteins with sub-cellular resolution, the MIBIscope platform provides scientists with new insights in understanding cell populations and interactions within the tumor microenvironment” said Harris Fienberg, CEO of IONpath. “We are committed to enable a streamlined workflow from visualization to quantitative data analysis and a partnership with Indica Labs will facilitate our users to integrate HALO with MIBI data for analyses such as cell segmentation and classification,” said Harris Fienberg, CEO of IONpath.

Indica Labs provides image analysis and image management solutions for digital pathology, including HALO®, HALO AITM and HALO LinkTM.  The HALO platform can analyze an unlimited number of fluorescent biomarkers within the spatial context of the tissue, making it an ideal image analysis solution for immuno-oncology and a natural complement to the multiplexed imaging capabilities provided by the MIBIscope system.

“There is a growing need amongst our customer base for technologies that can facilitate higher multiplexing, especially in the immuno-oncology research area,” said Dr. Kate Lillard Tunstall, CSO of Indica Labs.  “Together, the MIBI technology and HALO platform provide a complete end-to-end solution for multiplexing.  We are excited to work with IONpath to address the needs of our mutual customers.”

About Indica Labs, Inc.

Indica Labs software solutions provide fast, quantitative evaluation of whole slide tissues using HALO® and HALO AITM for image analysis and HALO LinkTM to manage images, data, and facilitate collaboration. With unmatched ease-of-use and scalability, pharmaceutical, healthcare, and research organizations worldwide are using HALO for high-throughput, whole-slide image quantification in areas such as oncology, immuno-oncology, neuroscience, ophthalmology, metabolism, respiratory, and toxicological pathology.  For more information, please visit or contact

About IONpath

IONpath™ is a venture-backed, commercial-stage company, founded by Stanford researchers out of the lab of Dr. Garry Nolan, focused on revolutionizing pathology with Multiplexed Ion Beam Imaging (MIBI) technology. MIBI is a multiplexed imaging platform with unmatched resolution, sensitivity, and throughput.   IONpath is headquartered in Menlo Park, CA.

For more information, please visit or contact

Scroll to Top